Register or Sign in to Save this opportunity, or Send an Inquiry.
Allergy Therapeutic for Co-development.
Pharmalicensing United States flag United States
Abstract ID:
An immunotherapy based on co-selection using a pair of complementary antibodies (i.e. anti-foreign and anti-anti-self antibodies) inducing tolerance to an inflammatory response.
Send an Inquiry
RE:
Participants
You
Type of Business Relationship Sought
Our client aspires to partner at the pre-clinical stage, with a medium to large Pharmaceutical company, for the development of its anti-inflammatory/cancer product. The company seeks a partner that is able to provide an upfront licensing fee in exchange for the first right to negotiate a global licensing agreement. The company is seeking, in order of priority: 1. A CRaDA (Collaborative Research and Development Agreement) / Licensing agreement Nature of Partnership: The partner would share / cover the cost of development providing upfront and milestone payments (full details to be discussed) 2. Divestment of $5M for development of technologies to IND
FEATURED
Last Updated Dec 2018
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION
Company Logo

Opportunity Contact